|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||
| Current assets | ||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||
| Marketable securities | ||||||||||||||||||
| Short-term investments | ||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||
| Total current assets | ||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||
| Assets held for sale | ||||||||||||||||||
| Long-term investments | ||||||||||||||||||
| Restricted cash | ||||||||||||||||||
| Operating lease right-of-use asset | ||||||||||||||||||
| Other non-current assets | ||||||||||||||||||
| Total assets | ||||||||||||||||||
| Liabilities and stockholders’ equity | ||||||||||||||||||
| Current liabilities | ||||||||||||||||||
| Accounts payable | ||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||
| Operating lease liability, current portion | ||||||||||||||||||
| Other current liabilities | ||||||||||||||||||
| Total current liabilities | ||||||||||||||||||
| Share repurchase liability | ||||||||||||||||||
| Operating lease liability, net of current portion | ||||||||||||||||||
| Other liabilities | ||||||||||||||||||
| Total liabilities | ||||||||||||||||||
| Series A convertible preferred stock, $0.0001 par value – no shares authorized, issued or outstanding as of December 31, 2023; 27,125,000 shares authorized, issued and outstanding as of December 31, 2022 | ||||||||||||||||||
| Total series A convertible preferred stock, $0.0001 par value – no shares authorized, issued or outstanding as of December 31, 2023; 27,125,000 shares authorized, issued and outstanding as of December 31, 2022 | ||||||||||||||||||
| Stockholders’ equity | ||||||||||||||||||
| Undesignated preferred stock, $0.0001 par value – 10,000,000 shares authorized as of June 30, 2025 and December 31, 2024, no shares issued or outstanding as of June 30, 2025 or December 31, 2024 | ||||||||||||||||||
| Common stock, $0.0001 par value – 140,000,000 voting shares authorized as of June 30, 2025 and December 31, 2024, 25,692,268 and 25,617,805 voting shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively; 10,000,000 non-voting shares authorized as of June 30, 2025 and December 31, 2024, no non-voting shares issued or outstanding as of June 30, 2025 or December 31, 2024 | ||||||||||||||||||
| Additional paid-in-capital | ||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||
| Common stock, shares authorized (in shares) | ||||||||||||||||||
Loading...
